Mebias Discovery, Inc

Mebias Discovery, Inc. is a biotech startup with a vision to unlock the full potential of GPCR drugs, as reflected in its slogan, "Mining the Full Potential of GPCR Drugs." Founded in 2015, Mebias has developed a groundbreaking platform to discover next-generation GPCR drugs without on-target side effects. Their expertise lies in G-protein Coupled Receptor (GPCR) therapeutics, which constitute approximately 30% of current prescribed drugs. Mebias leverages its understanding of protein dynamics and has access to two key technologies – native GPCR purification and protein nuclear magnetic resonance – to identify agonists lacking in other methodologies. The company boasts a series of biased mu opioid receptor scaffolds, including a clinical stage compound, and their platform significantly reduces time and costs for delivering optimized leads. Mebias' initial focus areas are CNS/Pain, OUD, Metabolic, and Inflammatory related disorders. Expertise/Assets: The company excels in the rapid identification and optimization of IND candidates devoid of on-target adverse effects. Mebias also offers a differentiated mu-opioid receptor agonist (MEB-1170) for the treatment of OUD and pain, lacking respiratory depression/GI motility issues/tolerance, and without demonstrating potential for abuse liability. Business Proposal: Mebias is seeking co-development and/or licensing opportunities for its mu-opioid drug candidates, as well as research funding/collaboration for lead discovery of additional targets in selected disease areas. The company has recently received a $630.68K Venture Round investment on 23 September 2022.